Loading…
Expression of IL-18 by SIV Does Not Modify the Outcome of the Antiviral Immune Response
Interleukin 18 (IL-18) is a proinflammatory cytokine expressed by several cell types, including activated dendritic cells and macrophages, that acts in synergy with IL-12 as an important amplifying factor for IFN-γ production and Th1 development. To study the immunological and virological effects of...
Saved in:
Published in: | Virology (New York, N.Y.) N.Y.), 2002-11, Vol.303 (2), p.327-337 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Interleukin 18 (IL-18) is a proinflammatory cytokine expressed by several cell types, including activated dendritic cells and macrophages, that acts in synergy with IL-12 as an important amplifying factor for IFN-γ production and Th1 development. To study the immunological and virological effects of IL-18 expression in the context of a lentiviral infection, we inoculated rhesus macaques with a high dose of replication-competent simian immunodeficiency virus (SIV) vectors carrying the rhesus IL-18 gene in the sense (SIV
IL-18) or antisense (SIV
FIGI) orientation. Both vectors behaved as attenuated viruses, resulting in low viral loads, induction of low and transient levels of inflammatory cytokines, no CD4
+ T cell depletion, and mild activation of T lymphocytes. Although IL-18-expressing virus could be isolated from some SIV
IL18-infected macaques for 12 weeks postinfection, the anti-SIV humoral and cellular immune responses of macaques inoculated with SIV
IL18 and SIV
FIGI were similar to each other, with the exception of an early IFN-γ response in animals infected with SIV
IL18. In summary, expression of IL-18 during the acute phase of SIV infection does not increase viral replication or influence the outcome of the antiviral immune response. |
---|---|
ISSN: | 0042-6822 1096-0341 |
DOI: | 10.1006/viro.2002.1647 |